Voloridge Investment Management LLC Sells 156,662 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Voloridge Investment Management LLC lowered its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 34.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 293,159 shares of the company's stock after selling 156,662 shares during the quarter. Voloridge Investment Management LLC owned approximately 0.13% of Sana Biotechnology worth $478,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC boosted its position in Sana Biotechnology by 229.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock valued at $25,000 after buying an additional 10,548 shares during the last quarter. Cerity Partners LLC bought a new stake in shares of Sana Biotechnology during the fourth quarter worth $25,000. Syon Capital LLC bought a new position in Sana Biotechnology in the fourth quarter valued at about $27,000. Ameriprise Financial Inc. acquired a new position in Sana Biotechnology during the 4th quarter valued at about $29,000. Finally, Blue Trust Inc. lifted its position in Sana Biotechnology by 51.0% during the 4th quarter. Blue Trust Inc. now owns 19,823 shares of the company's stock valued at $32,000 after purchasing an additional 6,694 shares during the period. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Stock Up 4.1%

Shares of SANA traded up $0.09 during midday trading on Tuesday, hitting $2.29. The company's stock had a trading volume of 378,937 shares, compared to its average volume of 3,465,442. Sana Biotechnology, Inc. has a one year low of $1.26 and a one year high of $8.17. The stock has a market capitalization of $516.34 million, a price-to-earnings ratio of -1.64 and a beta of 1.75. The company's fifty day simple moving average is $1.77 and its two-hundred day simple moving average is $2.33.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.02. On average, research analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Citizens Jmp upgraded Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a research report on Tuesday, March 18th. Jefferies Financial Group initiated coverage on Sana Biotechnology in a research report on Friday, March 14th. They set a "buy" rating and a $7.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $11.00 price target on shares of Sana Biotechnology in a research note on Thursday, April 24th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Sana Biotechnology presently has a consensus rating of "Moderate Buy" and an average price target of $10.80.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.